The new report* reviews catalyst events in the second quarter of 2012 regarding new and additional therapies that are being developed for several rare and niche diseases. These include Duchenne muscular dystrophy (DMD), Gaucher disease, Philadelphia chromosome negative (Ph-) acute lymphocytic leukemia (ALL), Fabry disease, and idiopathic pulmonary fibrosis (IPF).
One product, Elelyso (taliglucerase alfa) has already been approved by the FDA for the treatment of Gaucher disease, and provides patients with an alternative, lower-priced enzyme replacement therapy (ERT) option to Genzyme’s Cerezyme (imiglucerase), the market leader and standard of care, and Shire’s Vpriv (velaglucerase alfa).
The passage of the Orphan Drug Act in the United States in 1983 was the initial impetus behind the development of products for niche and rare diseases, and since that time, similar legislation has been enacted in the UK, Europe, Japan, Singapore and Australia. As a result of this global legislation, numerous products have been brought to market to treat diseases for which there were no existing therapies, saving countless lives worldwide.
Pharmaceutical and biotechnology companies are also increasingly focusing on developing products for these diseases as a means of reinvigorating their product pipelines. The market for these products is virtually wide open and will continue to be a major driving force in the industry.
*Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012
This report is an essential source of information and analysis on the global rare and niche diseases market, identifying key trends shaping and driving the global rare and niche diseases market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, it provides valuable insights on the pipeline products within the global rare and niche diseases sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
-ABOUT GLOBALDATA-
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com
